Because of concerns about a rise in serum creatinine and potassium levels, physicians may hesitate to prescribe angiotensin-converting enzyme inhibitor (ACEI)s/angiotensin II receptor blockers (ARB)s in patients with CRS. The gene discussed is ACE; the disease is congenital rubella syndrome.